Adherence to multiple sclerosis disease-modifying therapies in Ontario is low

Canadian Journal of Neurological Sciences

Volumn 38, Issue 3, 2011, Pages 429-433

  Wong, Janice ^a   Gomes, Tara ^a,b   Mamdani, Muhammad ^a,c   Manno, Michael ^a,b   O'Connor, Paul ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; CANADA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; POPULATION RESEARCH; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 79955513069     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100011823     Document Type: Article

References (14)

1. Rotstein DL, Mamdani M, O'Connor PW. Increasing use of disease modifying drugs for MS in Canada. Can J Neurol Sci. 2010;37 (3):383-8.
2. Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ. 2010;13(1):90-8.
3. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30(2):89-100.
4. Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin. 2010;26(3):663-74.
5. de Oliveira Tde M, Fiore AP, Fragoso YD. Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience. Patient Prefer Adherence. 2008;2:41-6.
6. Lafata JE, Cerghet M, Dobie E, et al. Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis. J Am Pharm Assoc (2003). 2008;48(6):752-7.
7. Cunningham A, Gottberg K, von Koch L, Hillert J. Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis. Acta Neurol Scand. 2010;121(3):154-60.
8. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11(3):306.
9. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol. 2008;59(3-4):131-5. (Pubitemid 351301255)
10. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003 Aug 26; 61(4):551-4. (Pubitemid 37025380)
11. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009 Apr;256(4):568-76.
12. Vinker S, Shani M, Baevsky T, Elhayany A. Adherence with statins over 8 years in a usual care setting. Am J Manag Care. 2008;14 (6):388-92. (Pubitemid 351928444)
13. Melo M, Qiu F, Sykora K, Juurlink D, Laupacis A, Mamdani M. Persistence with bisphosphonate therapy in older people. J Am Geriatr Soc. 2006;54(6):1015-16. (Pubitemid 43847052)
14. Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother. 2005;39(9):1401-8. (Pubitemid 41197117)